Stem cell ruling lamented, appealed

National Institutes of Health Director Francis Collins is "stunned" by the federal district judge's decision to deny federal funding for human embryonic stem cell research, and the Justice Department plans to appeal the ruling. Human embryonic stem cellsImage: Wikimedia commons, Nissim BenvenistyYesterday (August 24), Collins lamented to reporters about the more than $50 million in grants that had to be denied their annual renewals. "This very unexpected development" has dire consequences f

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
National Institutes of Health Director Francis Collins is "stunned" by the federal district judge's decision to deny federal funding for human embryonic stem cell research, and the Justice Department plans to appeal the ruling.
Human embryonic stem cells
Image: Wikimedia commons,
Nissim Benvenisty
Yesterday (August 24), Collins lamented to reporters about the more than $50 million in grants that had to be denied their annual renewals. "This very unexpected development" has dire consequences for both research projects already underway, as well as countless others that have yet to begin, said Collins. "Frankly, I was stunned, as was virtually everyone here at NIH, by the judicial decision yesterday," he said. "This decision has the potential to do serious damage to one of the most promising areas of biomedical research, and just at the time when we were really gaining momentum." The judge ruled that because hESC research is only possible after the destruction of embryos, any research involving these cell lines "is precluded from receiving federal funding." In addition to overturning President Barack Obama's 2009 executive order to expand those hESC lines eligible for federal funding, the ruling may negate the possibility of funding for even those lines allowed under former President George W. Bush. Yesterday, the US Department of Justice said it would appeal the ruling. In addition to the long list of diseases that hESCs have shown promise in treating, hESC research holds great potential in the area of drug development, Collins said. With regard to the NIH in particular, 50 grant proposals in the queue for peer review have been pulled from consideration because they involve hESC research, and $15-20 million worth of proposals that have passed the first stage of peer review with high scores and are awaiting counsel review have also been pulled. Finally, the injunction places a freeze on the annual renewal of another 22 grants totaling $54 million supporting "projects that are already well underway," Collins explained. Grants that have already been paid, which total $131 million this year alone, are permitted to continue -- until they come up for annual renewal next year, that is. "If this decision stands," Collins said, "very promising research on human diseases on which we need new insights and new options will not get done. Screening for new drugs using hESCs, a very promising way to discover new compounds, will stop. Researchers, who have been so energized by the opportunities made available over the last year, will likely grow discouraged, maybe move on to other countries or other fields of research. We will lose the momentum." He continued: "This is one of the most exciting areas of the broad array of engines of discovery that NIH supports. This decision has just poured sand into that engine of discovery."
**__Related stories:__***linkurl:NIH OKs 13 stem cell lines;http://www.the-scientist.com/blog/display/56196/
[2nd December 2009]*linkurl:NIH loosens stem cell consent rules;http://www.the-scientist.com/blog/display/55814/
[6th July 2009]*linkurl:Obama to lift stem cell ban;http://www.the-scientist.com/blog/display/55494/
]6th March 2009]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Jef Akst

    Jef Akst was managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide